EcoDrugPlus

Exportin 1

Ensembl ID : ENSNGAG00000022158
Gene Symbol: XPO1
3 Cross references
304 Possible Orthologues:

Expressed Sequence Ai182371

Ensembl ID : ENSNGAG00000013196
Gene Symbol: AI182371
1 Cross references
192 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSNGAG00000021807
Gene Symbol: FDFT1
3 Cross references
215 Possible Orthologues:

Fatty Acid Amide Hydrolase

Ensembl ID : ENSNGAG00000019634
Gene Symbol: FAAH
3 Cross references
131 Possible Orthologues:

Fibroblast Activation Protein Alpha

Ensembl ID : ENSNGAG00000022031
Gene Symbol: FAP
3 Cross references
127 Possible Orthologues:

Fibroblast Growth Factor 2

Ensembl ID : ENSNGAG00000019024
Gene Symbol: FGF2
3 Cross references
117 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSNGAG00000019988
Gene Symbol: FGFR1
3 Cross references
289 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSNGAG00000017837
Gene Symbol: FGFR2
3 Cross references
217 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSNGAG00000015713
Gene Symbol: FGFR3
3 Cross references
196 Possible Orthologues:

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSNGAG00000022737
Gene Symbol: FGFR4
3 Cross references
123 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSNGAG00000022615
Gene Symbol: FLT1
3 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSNGAG00000022203
Gene Symbol: FLT3
3 Cross references
133 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).